文献速递骨软组织肉瘤与黑色素瘤

端粒酶疫苗UV1联合伊匹木单抗与纳武利尤单抗对比双免疫治疗晚期黑色素瘤的随机II期研究

The telomerase vaccine UV1 combined with ipilimumab and nivolumab versus ipilimumab and nivolumab in advanced melanoma (INITIUM): A randomized open-label phase 2 study.
PubMed 文献 · Eur J Cancer · 2025-12-03

INITIUM研究为II期随机开放标签试验,纳入156例不可切除或转移性黑色素瘤患者,1:1随机接受伊匹木单抗3mg/kg联合纳武利尤单抗1mg/kg(4周期)加或不加UV1疫苗,后续纳武利尤单抗480mg每4周维持。主要终点盲法独立中心评估的无进展生存期(PFS)在两组间无显著差异(HR 0.95,95%CI 0.59-1.55),客观缓解率(ORR)分别为59.7%和59.2%,总生存期(OS)均未达到(HR 1.15,95%CI 0.60-2.20),≥3级治疗相关不良事件发生率分别为64.5%和65.4%。结论认为在初治晚期黑色素瘤中,UV1联合双免疫治疗未改善疗效。

要点

  • UV1联合伊匹木单抗+纳武利尤单抗未显著改善PFS(HR 0.95,95%CI 0.59-1.55)。
  • 两组ORR相近(59.7% vs 59.2%),OS均未达到(HR 1.15)。
  • ≥3级不良事件发生率两组相似(64.5% vs 65.4%)。

核心结论

  • 在初治晚期黑色素瘤患者中,UV1加入伊匹木单抗联合纳武利尤单抗未改善疗效。

研究设计与样本

  • II期随机开放标签试验,纳入156例不可切除或转移性黑色素瘤患者,1:1随机分组。
  • 试验组接受4周期伊匹木单抗3mg/kg联合纳武利尤单抗1mg/kg加UV1疫苗,对照组不加UV1,后续纳武利尤单抗480mg每4周维持。
  • 主要终点为盲法独立中心评估的PFS,次要终点包括OS、缓解评估和安全性。

主要发现

  • 中位PFS:UV1组34.3个月(95%CI 7.95-NR),对照组38.4个月(95%CI 8.15-38.37),HR 0.95(95%CI 0.59-1.55)。
  • 12个月PFS率两组均为57%(UV1组95%CI 45.0-68.1;对照组95%CI 44.6-67.0)。
  • ORR:UV1组59.7%,对照组59.2%(OR 1.12,95%CI 0.58-2.16)。
  • OS两组均未达到(HR 1.15,95%CI 0.60-2.20)。
  • ≥3级治疗中出现的不良事件发生率:UV1组64.5%,对照组65.4%。

临床怎么用

  • 对于初治晚期黑色素瘤,双免疫治疗基础上加用UV1疫苗未显示额外获益,暂不推荐常规联合。

局限性

  • 随访时间较短(至少18个月),OS数据尚未成熟。
  • II期试验样本量有限(156例),统计效能可能不足以检测微小差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Immune checkpoint inhibitor (ICI) combinations have improved outcomes in patients with advanced melanoma; however, long term survival remains poor. The addition of therapeutic cancer vaccines to ICI combinations represents a promising strategy to enhance efficacy. METHODS: In this phase 2, randomized, open-label trial, 156 patients with unresectable or metastatic melanoma were randomized 1:1 to receive 4 cycles of ipilimumab 3mg/kg and nivolumab 1mg/kg with or without UV1, a telomerase-targeted therapeutic cancer vaccine, followed by maintenance nivolumab 480 mg every 4 weeks. The primary endpoint was progression-free survival (PFS) based on blinded independent central review. Secondary endpoints included overall survival (OS), response assessments, and safety. RESULTS: At a minimum follow-up of 18 months, the projected median PFS was 34.3 months (95 % confidence interval [CI], 7.95 to NR) with ipilimumab-nivolumab-UV1 and 38.4 months (95 % CI, 8.15-38.37) with ipilimumab-nivolumab (hazard ratio, 0.95 [95 % CI, 0.59-1.55]). PFS at 12 months was 57 % (95 % CI, 45.0-68.1) and 57 % (95 % CI, 44.6-67.0) in the ipilimumab-nivolumab-UV1 and ipilimumab-nivolumab arms, respectively. Objective response rates were 59.7 % (ipilimumab-nivolumab-UV1) and 59.2 % (ipilimumab-nivolumab; odds ratio, 1.12; 95 % CI, 0.58-2.16). Median overall survival was not reached in either arm (hazard ratio, 1.15 [95 % CI, 0.60-2.20]). Grade > 3 treatment-emergent adverse events were reported in 64.5 % and 65.4 % of patients respectively. CONCLUSION: For patients with treatment naïve advanced melanoma, the addition of UV1 to ipilimumab-nivolumab did not result in improved efficacy compared with ipilimumab-nivolumab alone.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Lorigan P, Medina TM, Nyakas M, et al. The telomerase vaccine UV1 combined with ipilimumab and nivolumab versus ipilimumab and nivolumab in advanced melanoma (INITIUM): A randomized open-label phase 2 study. Eur J Cancer. 2025. PMID: 41365069. doi:10.1016/j.ejca.2025.116162

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。